Recombinant human growth hormone exacerbates chronic puromycin aminonucleoside nephropathy in rats. Growth failure is a cardinal feature of chronic renal failure in children. Administration of recombinant human growth hormone (rhGH) ameliorates this problem but may adversely affect the kidney and hasten the progression to end-stage renal disease. We conducted experiments to examine the impact of rhGH on the severity of chronic puromycin aminonucleoside (PAMN) nephropathy in rats. The glomerulopathy was induced by serial injections of PAMN over a 12 week period. Experimental animals (N = 6) received rhGH, 0.5 mg per dose, three times weekly, while control rats (N = 6) received hormone vehicle. rhGH had no effect on weight gain, hematocrit, or blood pressure in rats with the experimental renal disease. Urinary protein excretion increased approximately 50% in rhGH-treated rats with chronic PAMN nephropathy compared to untreated animals between four to eight weeks of the observation period. After 12 weeks, the inulin clearance was significantly lower in rhGH-treated rats, 0.26 0.05 versus 0.50 0.06 ml/minll00 g body wt in control PAMN animals, P < 0.05. Compared to untreated rats with PAMN nephropathy, administration of rhGH increased the extent of segmental glomerulosclerosis from 11 3 to 46 9% (P < 0.005) and elevated the tubulointerstitial injury score from 0.5 0.1 to 1.4 0.4 (P <0.05). Furthermore, glomerular hypertrophy was enhanced in animals with chronic PAMN nephropathy given rhGH, as evidenced by a larger glomerular planar area, 9.2 0.3 x l0-versus 11.9 0.5 x l0-mm2, P < 0.005. The renal cortical malondialdehyde content was higher in rhGH-treated rats with chronic PAMN nephropathy, 2.33 0.13 versus 1.78 0.06 nmol/mg protein in untreated animals with glomerular disease, P < 0.05. In normal rats with intact kidneys, rhGH administration (N = 4) increased glomerular filtration rate and glomerular planar area without altering blood pressure, proteinuria, renal cortical malondialdehyde content, or glomerular or tubulointerstitial damage, compared to untreated animals (N = 4). We conclude that administration of rhGH to rats with chronic PAMN nephropathy exacerbates the severity of the renal functional and structural injury in response to the epithelial cell toxin. These data suggest that caution should be exercised when prescribing rhGH for the treatment of short stature in children with chronic renal failure, especially those with glomerulopathies and persistent, severe nephrotic range proteinuria.
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One of the most important complications of chronic renal failure (CRF) in children is growth retardation [1] . The etiology of this problem is multifactorial including insufficient caloric intake, metabolic acidosis and renal osteodystrophy [2] . Although plasma levels of growth hormone (Gil) and insulin-like growth factor I (IGF-I) are within the normal range in pediatric patients with CRF, circulating uremic inhibitors or end organ responsiveness may interfere with the growth-promoting action of these peptide hormones [1, 2] .
The availability of recombinant human growth hormone (rhGH) has prompted a reassessment of the role of GH in the pathophysiology of short stature in children with CRF. Administration of rhGH for three weeks to rats with 5/6 nephrectomy enhances somatic growth compared to untreated uremic counterparts [3] . rhGH treatment for 6 to 12 months to prepubertal children with CRF consistently improves growth velocity without undue acceleration in bone maturation [4] [5] [6] .
Recently, there has been concern that GH may aggravate kidney disease and hasten the progression to end-stage renal failure. Transgenic mice carrying the bovine GH gene fused to the metallothionein-I promoter develop increased proteinuria and glomerulosclerosis [7] . The structural changes are associated with enhanced mesangial production of type IV collagen, laminin and heparan sulfate proteoglycans [8] . The severity of injury following renal ablation is attenuated in a mutant strain of dwarf rats that are selectively deficient in GH [9] . Finally, although rhGH administration for eight weeks to rats with 5/6 nephrectomy does not cause any deterioration in renal function, glomerular hypertrophy and glomerulosclerosis are increased in treated animals [10] .
It seems prudent to clarify the potential nephrotoxic effects of rhGH prior to embarking on widespread clinical use of this costly agent for the treatment of short stature in pediatric patients with CRF. Therefore, we conducted the following studies to assess the effect of rhGH on the course and severity of chronic puromycin aminonucleoside (PAMN) nephropathy, an experimental glomerulopathy characterized by heavy proteinuria and renal insufficiency.
standard rodent laboratory chow, containing 22% protein (Purina Mills, St. Louis, Missouri, USA). Because the pattern of weight gain was similar in the two groups of rats with chronic PAMN nephropathy, pair feeding was not employed in these studies. The rats weighed 110 to 130 g at the initiation of the experimental protocols.
Disease model Chronic PAMN nephropathy was induced over 12 weeks using the method described by Grond, Weening and Elema [11] .
Briefly, rats were given serial subcutaneous injections of the amount of rhGH needed for the administration of the hormone to all experimental animals on a given day, were stored frozen at -20°C. Therefore, the rhGH solution was thawed only once, ensuring stability of the drug for the entire 12-week study period. Experimental rats received 0.2 ml of the rhGH-PBS solution (0.5 mg of rhGH) as a subcutaneous injection three times per week for 12 weeks; control animals were given an equal volume of the vehicle.
Rats were weighed biweekly and blood pressure was measured each month in the awake conscious state using a tail cuff plethysmograph apparatus (Narco BioSystems, Houston, Texas, USA). Every two weeks, animals were placed in individual metabolic cages (Nalge, Rochester, New York, USA) to enable collection of 24-hour urine samples for determination of urinary osmolality, protein and creatinine concentrations. Rats were given free access to water but not food while they were in the metabolic cages. Each month, a fasting blood sample was obtained at the completion of the urine collection for measurement of hematocrit, serum Nat, creatinine, cholesterol, triglyceride, and albumin concentrations.
Inulin clearance At the end of the 12-week observation period, rats were anesthetized with mactin (100 mg/kg body wt) and placed on a heated animal operating table. The body temperature was monitored with a YSI telethermometer and maintained at 36.5 to 37.5°C throughout the study. A tracheostomy was performed, and the left external jugular vein was cannulated with PE-50 polyethylene tubing for infusion of [3H]-inulin. A suprapubic cystotomy was performed for the collection of urine into tared test tubes. Following preparation of the animal, 0.2 ml of a solution containing 12.5 mCi [3H}-inulin/ml was injected as a priming dose, followed by infusion of the same solution at a rate of 0.12 mI/hr. After a 30-minute equilibration period, three timed 30-minute urine collections were made, and midpoint blood specimens were obtained via the cut tail vein. Serum and urinary activities of [3H]-inulin were determined with a liquid scintillation counter (LKB Rackbeta). Inulin and creatinine clearances were calculated from the standard equation and the data are expressed as ml per mm per 100 g body weight.
Histopathology examination Rats were killed at the completion of the clearance studies. The kidneys were immersion-fixed in a 10% formalin solution and stained with hematoxylin-eosin and periodic acid-Schiff reagents. Segmental sclerosis was defined as localized collapse of capillary lumina and replacement with eosinophiic hyalinized material, occasionally accompanied by adhesions to Bowman's capsule. The number of segmentally sclerosed glomeruli was expressed as a percentage of the total number of glomeruli which exceeded 250 in each sample. The tubules and interstitium were examined for dilation, intratubular casts and tubular atrophy, interstitial infiltration with mononuclear cells, and replacement with fibrosis. The degree of tubulointerstitial changes was graded on a scale from 0 to 3+ as follows: 0, normal kidney; 1+, mild abnormalities affecting <25% of the renal parenchyma; 2+, moderate, 25 to 50% involvement; and 3+, severe, >50% of the kidney manifested abnormalities.
Glomerular planar area was determined using a computerized digitizing pad (Micro-plan II, Laboratory Computer Systems, Inc., Monsanto Corp., Natick, New York, USA) and surveying 40 to 50 glomeruli in each kidney specimen. Glomeruli throughout the cortex that were not globally sclerosed and that had clear delineation of the hilar region were included in this analysis.
Analytic methods
Serum Nat, glucose, creatinine, cholesterol and triglyceride and urinary Na and creatinine determinations were made using an automated analyzer (Beckman, Fullertown, California, USA). Serum albumin levels were assayed with the bromcresol green binding reagent (Sigma Chemical Co., St. Louis, Missouri, USA), and absorbance was monitored at 628 nm. Urinary protein concentration was measured using the Coomassie blue binding reagent (Bio-Rad, Richmond, California, USA) while urinary osmolality was determined with a vapor pressure osmometer (Wescor, Logan, Utah, USA).
Portions of the renal cortex were homogenized in 1.15% KCI solution (1:9 wtlvol) for assay of malondialdehyde content as described by Ohkawa, Ohishi and Yagi [121. A reaction mixture containing 0.2 ml of sample, 0.2 ml of 8.1% sodium dodecyl sulfate, 1.5 ml of 20% acetic acid adjusted to pH 3.5 with NaOH, and 1.5 ml of 0.8% aqueous solution of thiobarbituric acid was brought up to 4 ml with distilled water. The mixture was heated for 60 minutes at 95°C and then cooled with tap water, after which 1 ml of water and 5 ml of a mixture of n-butanol and pyridine (15:1, vollvol) were added. The sample was shaken vigorously and centrifuged at 4,000 rpm for 10 minutes, and the organic layer was removed. Absorbance was measured at 532 nm, using 1,1,3,3-tetramethoxypropane as a standard. The renal cortical lipid peroxide level was expressed as nmollmg protein. Statistical analysis The differences between groups were analyzed using Student's t-test and analysis of variance where appropriate. The experimental findings were considered statistically significant if P < 0.05.
Results
Administration of rhGH did not increase weight gain or hematocrit in rats with chronic PAMN nephropathy ( Table 1 ). In addition, despite the presence of impaired renal function, rhGH therapy did not cause sustained hyperglycemia in animals with PAMN-induced glomerular disease. Except for the eightweek time point when BP was higher in rats in Group IB, 147 2 versus 131 3 mm Hg in animals in Group IA, (P < 0.001), rhGH injections did not cause sustained hypertension in rats with renal disease.
The biochemical features of the nephrotic syndrome are summarized in Table 2 . Administration of rhGH to rats with chronic PAMN nephropathy did not aggravate the hyperlipidemia or hypoalbuminemia observed during the course of the glomerulopathy. Urinary protein excretion was elevated by approximately 50% in rhGH-treated rats with PAMN nephropathy (Group IB) between four to eight weeks of the study period (Fig. 1) . However, at the completion of the protocol, there was no difference in proteinuria between the two groups with PAMN nephropathy.
Urinary osmolality was lower in rats in Group IB, 682 83, than in Group IA, 905 60 mOsm/kg (P = 0.05). In addition, rhGH treatment of animals with chronic PAMN nephropathy was associated with an increased fractional excretion of Na, 0.66 0.15 (Group IB) versus 0.28 0.04% (Group IA), P < 0.05 (Table 3 ).
Prior to 12 weeks, the creatinine clearance was similar in Groups IA and lB (Fig. 2) . After 12 weeks, the creatinine clearance was reduced in rhGH-treated rats with PAMN nephropathy, 0.24 0.05 compared to 0.34 0.03 mI/mm/tOO g body wt in control PAMN rats. This finding was confirmed by measuring the inulin clearance, 0.50 0.06 in Group IA versus 0.26 0.05 ml/min/100 g body wt in Group IB, P < 0.02 (Fig.  3) . Total kidney weight was comparable in untreated PAMN Renal histopathology studies indicated that administration of rhGH to rats with chronic PAMN nephropathy worsened the parenchymal injury. The percentage of segmentally sclerosed glomeruli was higher in Group 18, 46 9%, than in Group IA, 11 3 (P < 0.005); the tubutointerstitial injury score paralleled the glomerular damage, that is, 1.4 0.4 in Group lB versus 0.5 0.1 in Group IA (P < 0.04) (Table 4) . Furthermore, the glomerular planar area was enlarged in rats with chronic PAMN nephropathy given rhGH (Group IB), 11.9 0.5 compared to 9.2 0.3 x iO mm2 in untreated animals in Group IA (P < 0.005; Fig. 4 ). The administration of rhGH to intact rats with normal kidney function (Group IIB) had no demonstrable effect on somatic growth, blood pressure, hematocrit or serum glucose concentration compared to normal rats receiving no therapy (Group hA; Table I ). rhGH did not alter the serum albumin, cholesterol, triglycerides or creatinine concentration in normal rats (Table 2 ). In addition, there was no increase in urinary protein excretion in Group 118 animals (Fig. 1) . Urinary osmolality and fractional excretion of Na were comparable in animals in Groups IIA and JIB (Table 3) .
Although there was no rhGH-induced alteration in creatinine clearance (Fig. 2) , the inulin clearance was greater in Group IIB, 0.79 0.06, than in Group hA, 0.65 0.08 mI/mm 100 g body wt (P < 0.02; Fig. 3 ). Hormonal therapy did not promote glomerulosclerosis or tubulointerstitial damage in the animals in Group JIB compared to the untreated rats in Group hA (Table   4 and Fig. 6 ). However, rhGH treatment did expand the glomerular planar area from 4.6 0.3 (Group hA) to 5.8 0.4 x 1o mm2 (Group JIB) (P < 0.03; Fig. 4 ). Finally, rhGH administration did not promote lipid peroxidation in normals rats. The renal cortical malondialdehyde was 1.34 0.09 in the rats in Group IJA and 1.29 0.09 nmol/mg protein in rhGHtreated normal rats in Group JIB.
Discussion
The results of this study indicate that administration of rhGH to rats with chronic PAMN nephropathy exacerbates renal functional and structural damage induced by this epithelial cell toxin. This was manifested as a decline in GFR after 12 weeks, increased glomerular hypertrophy, worsening of glomerulosclerosis and increased tubular atrophy, interstitial infiltration with mononuclear cells and fibrosis. rhGH treatment promoted increased lipid peroxidation of the renal parenchyma. In normal rats, rhGH treatment caused markedly different changes in renal structure and function. Thus, although there was no change in proteinuna or renal cortical malondialdehyde content, glomerular planar area and inulin clearance were increased.
It is important to acknowledge the magnitude of the rhGH dose that was provided to rats in Groups lB and IIB. The animals received approximately 3 mg/kg/week of the hormone, tenfold greater than the standard dose of rhGH given to children with short stature, that is, 0.3 mg/kg/week [13] . A twofold larger dose was used in a previous study investigating the impact of GH in rats with CRF [10] . The rationale for its use is to facilitate the detection of an adverse effect of rhGH within the time frame of the experimental regimen. In addition, provision of a large dose ensures that a pharmacologic level of GH is achieved in the plasma and eliminates any confounding effect of antibody production by rats to rhGH. The fact that rats with normal renal function tolerated the administration of rhGH without overt sequelae suggests that the hormone was free of systemic toxicity and that the adverse effects of rhGH were confined to the kidney. Substantial data indicate the potential harm to the kidney that may result from rhGH treatment. Mesangial accentuation and glomerulosclerosis develop in mice that are transgenic for bovine GH [7] . Initially, there is increased number of centrolobular glomerular cells [14] , followed by enhanced production and accumulation of extracellular matrix materials [8] . These abnormalities could not be reproduced in mice that were transgenic for IGF-I [7] . The severity of glomerulosclerosis in aging rats correlates with circulating plasma levels of GH [15] .
The effect of GH has been studied in various models of kidney disease. Administration of bovine GH for 10 to 17 days has no demonstrable effect on the glomerular filtration rate or renal histopathology in rats with reduced renal mass [16] .
Extended rhGH treatment for eight weeks to animals with 5/6 nephrectomy does not alter the inulin clearance; however, it promotes glomerular hypertrophy and glomerulosclerosis [10] . Genetic deficiency of GH in mutant dwarf rats attenuates the hypertension, proteinuria and progressive renal parenchymal destruction following 5/6 nephrectomy compared to the wild strain with a remnant kidney [9] . In corticosteroid-treated rats with passive Heymann nephritis that are given rhGH there is no change in proteinuria or creatinine clearance [17] .
It is likely that the potential for GH-induced renal damage is directly related to the seventy of the underlying disease process. In chronic PAMN nephropathy, there is steady exposure of the glomerulus to the toxin, unremitting injury to glomerular epithelial cells, mesangial cell dysfunction [18] and more rapid deterioration in kidney function compared to the experimental models described above. The proteinuria, hypoalbuminemia and hyperlipidemia are more severe in chronic PAMN nephropathy than in other experimental models of chronic renal disease.
The level of proteinuria and the biochemical indices of the nephrotic syndrome were comparable in the two groups of rats with PAMN nephropathy. This suggests that rhGH treatment was an additional factor that contributed to the development of increased kidney damage in rats with glomerular disease.
Following acute intravenous injection of PAMN, provision of allopurinol, superoxide dismutase, and the hydroxyl radical scavengers, dimethylthiourea and sodium benzoate, reduces proteinuria and lessens the renal parenchymal damage [19, 20] . Glucocorticoids enhance the activity of endogenous glomerular antioxidant enzymes and attenuate lipid peroxidation of glomerular tissue [21] . Reactive oxygen molecules are also involved in the pathogenesis of chronic PAMN nephropathy. Dietary supplementation with the antioxidant amino acid, taunne, attenuates the structural and functional injury to the kidney, in conjunction with reduced renal cortical malondialdehyde content [22] . rhGH may foster increased lipid peroxidation in the renal parenchyma by stimulating macrophages and mononuclear cells that infiltrate the glomeruli and tubulointerstitium of rats with PAMN nephropathy [23, 24] . The deterioration of kidney function in experimental models of renal disease may be mediated by alterations in single nephron blood flow and increased intraglomerular pressure [25] . Glomerular hypertrophy and the response to circulating, paracrine, and autocrine peptide growth factors may also contribute to the inexorable loss of renal function [26] . We did not measure intrarenal hemodynamics in these experiments. However, the effect of rhGH on glomerular planar area supports the However, as we observed in our study, considerable renal damage can occur during the course of rhGH therapy that is not manifested by changes in the serum creatinine concentration [31] . Furthermore, analogous to experimental kidney disease, the nephrotoxicity of rhGH in children may be critically dependent upon the severity of the underlying renal disease. The studies reporting the efficacy of rhGH treatment in children with CRF include primarily (37 of 51) children with dysplasia, obstructive uropathy or tubular disorders [4-6, 28, 30] . Moreover, six of the 14 patients with glomerular disease were free of "massive proteinuria" [28] . Most studies do not stratify patients according to the antecedent rate of decline in kidney function. While the potential for renal damage induced by rhGH may be minimal in children with normal kidney function or whose renal disease is likely to deteriorate slowly, renal damage due to rhGH may be exaggerated in pediatric patients whose CRF is a consequence of severe, rapidly progressive glomerulopathies. In support of this contention, we measured microalbuminuria in 17 short children with normal renal function who received rhGH therapy for at least one year. There was no increase in this sensitive index of glomerular dysfunction compared to 13 growth impaired patients who were not given rhGH [32] . In addition, the growth rate was accelerated in nine children with renal transplants treated with rhGH; however, there was a 24% decline in creatinine clearance during the course of therapy and treatment was discontinued in two patients because of a rising serum creatinine [33] .
In conclusion, we have demonstrated that administration of rhGH to rats with chronic PAMN nephropathy results in diminished renal function, enhanced glomerular hypertrophy and marked worsening of glomerular sclerosis and tubulointerstitial scarring. This deleterious effect on renal function occurred in the absence of any detectable effect of rhGH on blood pressure, anemia, intermediary metabolism or the severity of the biochemical indices of the nephrotic syndrome. Although the numbers of animals that were studied are relatively small and the duration of follow-up was limited, we suggest that References caution should be exercised in prescribing rhGH for the treatment of short stature in children with CRF, especially those with underlying glomerular diseases and persistent nephrotic syndrome. Although proteinuria per se is unlikely to be the primary glomerulopathic factor, massively increased urinary protein excretion and more rapid disease progression may be markers of an enhanced susceptibility to rhGH-induced kidney damage in these patients. Additional studies with a variety of experimental models of renal disease associated with a range of proteinuria are needed to address this issue. Continued evaluation of this important therapeutic modality is needed before rhGH can be routinely utilized for the reversal of stunted growth in the child with CRF.
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